Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

2020417 citationsJournal Articlegreen Open Access

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 22, Issue 1, pp. 107-117

Field-Weighted Citation Impact: 36.94